Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Account Payables
Amounts the company owes suppliers for goods and services received.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 50.0% from a year ago
Account payables stood at $279.62K at the end of Q1 FY2026, down 50.0% from a year earlier and down 47.9% from the prior quarter. Over 3 fiscal years it compounded at +9.9% a year.
Context
- Account payables amounted to 4.8% of total assets at the end of Q1 FY2026, down 108.9 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -50.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 536.77K USD
- Year-over-year change
- -8.6%
- 4-year CAGR
- +131.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 536.77K | -8.6% |
| FY2024 | 2024-12-31 | 587.54K | -16.9% |
| FY2023 | 2023-12-31 | 707.19K | +75.0% |
| FY2022 | 2022-12-31 | 404.22K | +2057.6% |
| FY2021 | 2021-12-31 | 18.74K | — |
Account Payables vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 account payables of $279.62K is the lowest of the 6 companies compared; the peer median is $3.15M.
- Its year-over-year change of -50.0% is the 5th highest of 6, against a peer median of -27.1%.
- Account payables amounts to 4.8% of total assets for TELO, versus a peer median of 3.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.68M | -35.8% | +14.4% | 18.1% | |
| Mar 2026 | $4.28M | -27.1% | +13.0% | 3.3% | |
| Mar 2026 | $3.15M | -11.8% | -4.3% | 1.0% | |
| Mar 2026 | $1.3M | -57.7% | -42.5% | 2.1% | |
| Mar 2026 | $1.01M | -9.8% | +107.8% | 5.1% | |
| Mar 2026 | $279.62K | -50.0% | +9.9% | 4.8% | |
| Peer median (excluding TELO) | $3.15M | -27.1% | +13.0% | 3.3% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.